

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

JUBLIA
(efinaconazole topical solution)

Status: CVS Caremark® Criteria

Type: Initial Prior Authorization with Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Jublia (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to *Trichophyton rubrum* and *Trichophyton mentagrophytes*.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for onychomycosis of the toenail(s) due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*

AND

- The patient's diagnosis has been confirmed with a fungal diagnostic test (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy)

AND

- The patient has experienced an inadequate treatment response to an oral antifungal therapy (e.g., terbinafine, itraconazole)

OR

- The patient has experienced an intolerance to an oral antifungal therapy (e.g., terbinafine, itraconazole)

OR

- The patient has a contraindication that would prohibit a trial of an oral antifungal therapy (e.g., terbinafine, itraconazole)

AND

- The requested drug is not being used in a footbath

AND

- If additional quantities are required, multiple toenails are being treated

Quantity Limits Apply.

Treatment of a single toenail: 4 mL per 21 days* or 12 mL per 63 days*

Treatment of multiple toenails: 16 mL per 21 days* or 48 mL per 63 days*

*The duration of 21 days is used for a 28-day fill period and 63 days is used for an 84-day fill period to allow time for refill processing.

Duration of Approval (DOA):

- 1160-C: DOA: 12 months

REFERENCES

1. Jublia [package insert]. Bridgewater, NJ: Bausch Health US LLC; March 2022.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed August 7, 2023.

Jublia PA with Limit Policy 1160-C UDR 10-2023

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428B 021423

3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 08/07/2023).
4. Frazier WT, Santiago-Delgado ZM, Stupka KC. Onychomycosis: Rapid Evidence Review. *American Academy of Family Physicians*. 2021;104:359-368.
5. Centers for Disease Control (CDC) and Prevention. Fungal Nail infections. Available at: <https://www.cdc.gov/fungal/nail-infections.html>. Accessed August 7, 2023.
6. Lipner SR, Scher RK. Efinaconazole in the treatment of onychomycosis. *Infect Drug Resist*. 2015;8:163–172.

Jublia PA with Limit Policy 1160-C UDR 10-2023

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428B 021423